The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2021 Apr 19; 63(1622):57-64
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation…
Med Lett Drugs Ther. 2017 May 8; 59(1520):71-82
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation H 1 -antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Treat Guidel Med Lett. 2013 May; 11(129):43-52
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
The FDA has approved a nasal spray fixed-dose combination ( Dymista – Meda) of the H 1 -antihistamine azelastine ( Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate ( Flonase, and…
Med Lett Drugs Ther. 2012 Oct 29; 54(1402):85-7
The FDA has approved a nasal spray fixed-dose combination ( Dymista – Meda) of the H 1 -antihistamine azelastine ( Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate ( Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H 1 -antihistamine and a corticosteroid.
The FDA has approved 2 intranasal HFA (hydrofluoroalkane) aerosols of the corticosteroids beclomethasone dipropionate ( Qnasl – Teva Respiratory) and ciclesonide ( Zetonna – Sunovion) for once-daily…
Med Lett Drugs Ther. 2012 Oct 15; 54(1401):84
The FDA has approved 2 intranasal HFA (hydrofluoroalkane) aerosols of the corticosteroids beclomethasone dipropionate ( Qnasl – Teva Respiratory) and ciclesonide ( Zetonna – Sunovion) for once-daily treatment of seasonal and perennial allergic rhinitis. They are the first HFA nasal steroids to become available in the US (HFA propellants do not deplete the ozone layer). Both drugs are already available for these indications as aqueous nasal sprays. Aqueous ("wet") formulations can cause adverse effects such as postnasal drip, moist feeling in the nose, strong odor, and bitter aftertaste, which could reduce patient compliance and may lead to discontinuation of the medication; the new pressurized, odorless, non-aqueous ("dry") HFA formulations may be better tolerated. Download complete U.S. English article